FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy By Ogkologos - July 1, 2026 195 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CADENZA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... December 17, 2020 EMA Recommends Extension of Indications for Selumetinib October 9, 2025 Despite Proven Safety of HPV Vaccines, More Parents Have Concerns October 22, 2021 No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in... September 26, 2024 Load more HOT NEWS Cancer in My Community: Addressing Regional Cancer Disparities in Peru Sun Exposure Lowers Risk of Breast Cancer, Study Finds Two Large Studies with New Screening Tests Show Promise for Increasing... On your marks, get set… start-up!
